DEC 15, 2018 4:18 PM PST

HIV Vaccine Successful in Non-human Primates

WRITTEN BY: Carmen Leitch

Researchers have been trying to create a vaccine for HIV, the virus that causes AIDS, for decades. Scientists at Scripps Research have reported new work in the journal Immunity that has shown that an experimental vaccine strategy they developed has been successful in a non-human primate model - rhesus macaque monkeys. The monkeys produced antibodies against a strain of HIV that is similar to one commonly infecting people, which is called a Tier 2 virus. This is also the first work to demonstrate the level of antibodies that a vaccine needs to produce in order to protect a person against HIV infection.

This image shows new HIV particles exiting an infected T-cell. / Credit: National Institutes of Health

"We found that neutralizing antibodies that have been induced by vaccination can protect animals against viruses that look a lot like real-world HIV," said Dennis Burton, Ph.D., chair of Scripps Research's Department of Immunology and Microbiology, and scientific director of the International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and of the National Institutes of Health's Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID).

It’s still a long way from clinical trials in people, but this work shows that the strategy developed by Burton and colleagues should be pursued. The scientists aim to find the vulnerable parts of the virus and teach the human immune system to generate antibodies that will attack those parts. 

Previous work led by Scripps Research investigators pinpointed the outer envelope protein trimer of the virus as a vulnerability. Animal studies confirmed that antibodies were effective on the area. The trimer is unstable, however, and difficult to use in a vaccine. Eventually, researchers were able to create a more stable version of the trimer, called SOSIP, in 2013.

"For the first time, we had something that looked pretty much like the HIV envelope protein trimer," explained the co-first author of the new report, Matthias Pauthner, Ph.D., a research associate at Scripps Research.

The scientists designed a vaccine that contained the SOSIP trimer and went to work investigating whether animals were protected. Investigators had already learned that some monkeys had low antibody levels, or titers, after being exposed to the vaccine but in other monkeys, titers were high. In this work, they re-vaccinated six low- and six high-titer monkeys, and twelve that were unimmunized.

The re-vaccinated primates were exposed to SHIV, a simian version of HIV with an envelope trimer that matches the human one. Like circulating HIV strains that infect people, SHIV is a Tier 2 virus because it is tough to neutralize. In the high-titer animals that were re-vaccinated, however, the strategy prevented infection.

"Since HIV emerged, this is the first evidence we have of antibody-based protection from a Tier 2 virus following vaccination," said Pauthner. "One question now is how can we get such high titers into every animal?"

Titers are important to watch because protection from HIV waned as time went on, and titers fell. The researchers saw that titers had to be maintained to keep up the shield against HIV. Those neutralizing antibodies were critical to stopping the virus, unlike other parts of the immune system. Pauthner noted the significance of this finding; other labs often use immune T cells in their work instead.

The scientists want to keep titers high and improve the vaccine for human trials. "There are many immunological tricks that can be explored to make immunity last longer," said Pauthner.

Next, the investigators are going to attempt to use molecules called broadly neutralizing antibodies (bnAbs), which are effective against many different HIV strains instead of just one, like these studies. This work helps lay the foundation for those future work. "This research gives an estimate of the levels of bnAbs that we may need to induce through vaccination in order to protect against HIV globally," explained Burton.

Learn more about why it’s important to create a vaccine for HIV from the video above by Harvard University.

Sources: AAAS/Eurekalert! Via Scripps Research Institute, Immunity

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JAN 20, 2020
JAN 20, 2020
Ovarian Cancer Protein Accelerates Alzheimer's Neurodegeneration
Around 21,000 people in the US are diagnosed with ovarian cancer every year, while an estimated 5.8 million Americans have Alzheimer’s. Now, research
JAN 23, 2020
Cell & Molecular Biology
JAN 23, 2020
Scientists Engineer Venom-Producing Organoids
Snake venom is also a source of therapeutics, and a potential source of new medicines.
FEB 09, 2020
Genetics & Genomics
FEB 09, 2020
Mosquitoes are Driven to Search for Heat in the Hunt for Meals
Mosquitoes can be dangerous disease vectors, and they infect and kill hundreds of thousands of people with illnesses like dengue, malaria, and West Nile Virus.
MAR 02, 2020
Cell & Molecular Biology
MAR 02, 2020
Pushing the Limits of Ribosomes
Researchers engineer mutant ribosomes that can create biopolymers that are not found in nature.
MAR 15, 2020
Cell & Molecular Biology
MAR 15, 2020
Immune Cells Can Attack Tumors Remotely
The body's immune system is able to identify the cancerous cells of a tumor and launch an attack against them.
MAR 20, 2020
Health & Medicine
MAR 20, 2020
Why Does COVID-19 Kill So Many Older People?
Since early statistics began to emerge from China, it seemed that COVID-19 tended to affect older people more than younger ones. And now, data from Italy i
Loading Comments...